Kyprolis ENDEAVOR data signal a changing of the guard for multiple myeloma treatment

Exelixis’s novel kinase inhibitor zanzalintinib has shown promise in a metastatic colorectal cancer population but some experts want to see more data before passing judgement on whether it can become a new chemotherapy-free treatment option for these patients.

The Paris-based group is paying €350m upfront to get hold of Marseille-headquartered ImCheck's acute myeloid leukemia candidate.

Galapagos is closing its cell therapy business after a prolonged search for buyers, leading to job cuts and site closures in the US, Netherlands, Switzerland and China.

Frontrunner believes it can gain a first approval in EGFR+ lung cancer, even though the FDA recently raised the bar on overall survival.